Compare Freeport-McMoRan Inc (FCX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Merck & Co., Inc. — how do they compare? Freeport-McMoRan Inc trades at $73 (market cap $103.19B), while Merck & Co., Inc. trades at $142.38 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 3.4× Freeport-McMoRan Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Merck & Co., Inc. for 98 Days on average.
| FCX | MRK | |
|---|---|---|
Market Cap | $103.19B | $352.29B |
Volume | 11,744,911 | 6,348,796 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $156.43 |
52-Week Low | $38.65 | $82.49 |
Typical Hold Time | 69 Days | 98 Days |
Enterprise Value | $109.47B | $399.05B |
Dividend Yield | 0.83% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.13, down 1.98% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $72.27. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong operating cash flow of $5.61 billion in 2025 supports ongoing expansion projects amid favorable copper demand trends.
The outlook for FCX is positive, driven by robust copper demand from AI and data center growth, but risks include rising production costs and a legal investigation. Wall Street sentiment is bullish with 61% buy ratings, though the stock faces near-term resistance at $72.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
